UK MHRA Guidance: Medicines: Reclassify Your Product

Sharan Murugan
2 hours ago
3 min read

Reclassification of medicines is an important regulatory mechanism that allows changes to the legal supply status of a medicinal product in the United Kingdom. The UK guidance on reclassification explains how applicants can apply to change the classification of a medicine, outlines procedural pathways, and clarifies the regulatory expectations associated with such changes.

Using the Reclassification Guidance

The guidance is intended for marketing authorisation holders or applicants who wish to change the legal classification of a medicine. It provides practical direction on eligibility, procedural routes, evidence requirements, and stakeholder consultation.

Applicants are expected to review the guidance carefully to determine whether their product is suitable for reclassification and to understand the regulatory standards that must be met before submission.

Overview

Reclassification involves changing the legal status under which a medicine is supplied to the public. This process is designed to ensure that medicines are available in a manner that balances accessibility with patient safety.

Any change in classification must be supported by evidence demonstrating that the medicine can be used safely and effectively under the proposed new conditions of supply. The decision to reclassify a medicine is based on a comprehensive assessment of benefit–risk balance, safety profile, and the need for medical supervision.

Classifications of Medicines

In the UK, medicines are generally classified into three categories:

Prescription Only Medicines (POM) – supplied only with a prescription from an authorised healthcare professional.
Pharmacy Medicines (P) – available without prescription but sold under the supervision of a pharmacist.
General Sales List (GSL) Medicines – available for sale in general retail outlets without pharmacist supervision.

Each classification reflects the level of control necessary to ensure safe and appropriate use.

Changing the Legal Classification of a Medicine

Applicants seeking to change the legal classification must submit a variation to the existing marketing authorisation or include the request within a new application. The application must include supporting data to justify that the proposed reclassification will not compromise patient safety.

Evidence may include clinical data, post-marketing experience, risk mitigation measures, labelling updates, and educational materials where relevant. The authority evaluates whether the product can be used safely without prescription or with reduced supervision, depending on the proposed category.

Reclassification decisions consider misuse potential, complexity of diagnosis, risk of adverse reactions, and clarity of instructions for use.

Types of Reclassification Procedure

The guidance outlines different procedural routes depending on the nature of the request. Reclassification may involve:

Switching a product from POM to P
Switching from P to GSL
Direct reclassification from POM to GSL in specific circumstances

Each procedure requires appropriate justification and may involve regulatory review timelines aligned with variation procedures.

Public and Professional Input

Reclassification proposals are subject to consultation processes. Public and professional input plays a key role in ensuring transparency and assessing potential impact on healthcare practice.

Consultation may involve healthcare professionals, patient groups, and other stakeholders. Feedback is considered during the decision-making process to ensure that reclassification aligns with public health priorities and practical use conditions.

Additional Information

The guidance includes further details on documentation requirements, assessment considerations, and post-approval obligations. Applicants are advised to ensure that product information, labelling, and risk communication materials are updated to reflect the new legal classification if approved.

Proper implementation following approval is essential to maintain compliance and ensure that supply conditions are clearly communicated.

Legal Status of Substances

The guidance also references the legal status of specific substances. Applicants should verify whether a substance is already subject to classification restrictions before submitting a reclassification request.

Understanding the current legal status of active substances is essential when planning development or lifecycle management strategies.

Marketing authorisation holders considering reclassification should carefully assess their product’s safety profile, post-marketing data, and risk mitigation strategies before submission.